Abbott Laboratories (SNSE:ABTCL)
Chile · Delayed Price · Currency is CLP | Market Cap | 174.80T -18.2% |
| Revenue (ttm) | 42.92T +8.1% |
| Net Income | 4.98T -61.2% |
| EPS | 2,847.33 -61.2% |
| Shares Out | n/a |
| PE Ratio | 35.13 |
| Forward PE | 18.48 |
| Dividend | 2,265.12 (2.30%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 98,576 |
| Day's Range | n/a |
| 52-Week Range | 77,020 - 119,500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott price target lowered to $125 from $135 at UBS
UBS analyst Patrick Wood lowered the firm’s price target on Abbott (ABT) to $125 from $135 and keeps a Buy rating on the shares after assuming coverage of the name.
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader acces...
Abbott defeats shareholder lawsuit over 2022 infant formula recall
A federal judge on Friday dismissed a lawsuit accusing Abbott Laboratories of defrauding shareholders by downplaying and trying to evade its responsibility for a 2022 recall of powdered infant formu...
Abbott investigates two separate cyber incidents, says no operations affected
Abbott Laboratories is investigating two cyber incidents involving unauthorized access to some internal systems at its cancer diagnostics business and its LabCentral portal, the company said on Frid...
Abbott price target raised to $115 from $102 at BofA
BofA analyst Travis Steed raised the firm’s price target on Abbott (ABT) to $115 from $102 and keeps a Buy rating on the shares. Q2 results were “better than feared”…
Abbott price target raised to $120 from $110 at JPMorgan
JPMorgan raised the firm’s price target on Abbott (ABT) to $120 from $110 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first on…
Abbott price target raised to $118 from $115 at Piper Sandler
Piper Sandler raised the firm’s price target on Abbott (ABT) to $118 from $115 and keeps an Overweight rating on the shares. The firm notes the company’s reported Q2 results…
Abbott price target raised to $112 from $108 at Citi
Citi raised the firm’s price target on Abbott (ABT) to $112 from $108 and keeps a Buy rating on the shares. The firm views the company’s Q2 report as “very…
Abbott’s Q2 gives confidence in improving results, says William Blair
William Blair reiterated an Outperform rating on Abbott (ABT) Laboratories, noting that the shares traded up over 10% on Q2 results that help alleviate concerns about medtech end-markets, the recent…
Abbott Laboratories Stock (ABT) Rallies on a Q2 Earnings Beat and a 2026 EPS Guidance Increase
Abbott Laboratories stock took off on Thursday after the company posted strong earnings and updated its EPS guidance.
Abbott Laboratories Earnings Call Transcript: Q2 2026
Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding expectations. Full-year sales growth guidance was reaffirmed and EPS guidance raised, with strong momentum in nutrition, diagnostics, and medical devices. Key product launches and pipeline investments support future growth.
Abbott Laboratories Earnings release: Q2 2026
Abbott Laboratories released its Q2 2026 earnings on July 16, 2026, summarizing the period's financial results.
Abbott Laboratories Slides: Q2 2026
Abbott Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Abbott Laboratories Quarterly report: Q2 2026
Abbott Laboratories has published its Q2 2026 quarterly earnings report on July 16, 2026.
Abbott Laboratories Sales Rise on Diagnostics Growth
The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.
Abbott reports Q2 adjusted EPS $1.31, consensus $1.28
Reports Q2 revenue $12.59B, consensus $12.52B. “Our second-quarter results reflect the momentum we are building,” said Robert B. Ford, chairman and chief executive officer, Abbott (ABT). “We expect th...
Abbott raises FY26 adjusted EPS view to $5.45-$5.60 from $5.38-$5.58
FY26 consensus $5.48. Abbott (ABT) projects full-year 2026 comparable sales growth of 6.5% to 7.5%, consensus $50.26B.
Abbott raises 2026 profit forecast on heart device strength
Abbott raised its annual profit forecast on Thursday, as it expects strong demand for its heart devices in the second half of the year.
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 Abbott reaffirms full-year 2026 com...
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks be...
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
The U.S. Justice Department closed a criminal probe into Abbott Laboratories over how it managed a baby formula facility where potentially deadly bacteria were discovered and suspected of cau...
The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.
WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; up pointing triangle over how it managed a baby formula facility where potentially deadly bacteria wa...
Abbott hosts conference call for second-quarter earnings
ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens.